Overview
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
Status:
Completed
Completed
Trial end date:
2011-05-01
2011-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is <2000.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hoffmann-La RocheTreatments:
Interferon-alpha
Peginterferon alfa-2a
Peginterferon alfa-2b
Criteria
Inclusion Criteria:- adult patients, >/= 18 years of age
- chronic hepatitis C
- informed consent to data collection
Exclusion Criteria:
- co-infection with HIV or HBV
- previous treatment with peginterferon and/or ribavirin